EZZ Life Science Holdings Ltd Net Assets
EZZ Life Science Holdings Ltd net assets. Based on the latest financial reports, EZZ Life Science Holdings Ltd (EZZ) has net assets worth AU$27.81 Million AUD (≈ $19.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$32.60 Million ≈ $23.07 Million USD) and total liabilities (AU$4.80 Million ≈ $3.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore EZZ net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$27.81 Million |
| % of Total Assets | 85.29% |
| Annual Growth Rate | 500.18% |
| 5-Year Change | 177.86% |
| 10-Year Change | N/A |
| Growth Volatility | 288215.59 |
Net Assets of EZZ Life Science Holdings Ltd (2017–2024)
Net assets of EZZ Life Science Holdings Ltd from 2017 to 2024. This chart illustrates how EZZ Life Science Holdings Ltd's net assets have evolved over time, based on quarterly financial data. See EZZ Life Science Holdings Ltd net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for EZZ Life Science Holdings Ltd (2017–2024)
The table below shows the annual net assets of EZZ Life Science Holdings Ltd from 2017 to 2024. For live market cap and overall valuation, see EZZ stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$28.09 Million ≈ $19.87 Million |
+31.71% |
| 2023-12-31 | AU$21.32 Million ≈ $15.09 Million |
+46.23% |
| 2022-12-31 | AU$14.58 Million ≈ $10.32 Million |
+28.05% |
| 2021-12-31 | AU$11.39 Million ≈ $8.06 Million |
+12.66% |
| 2020-12-31 | AU$10.11 Million ≈ $7.15 Million |
+28.71% |
| 2019-12-31 | AU$7.85 Million ≈ $5.56 Million |
+853.14% |
| 2018-12-31 | AU$823.91K ≈ $582.97K |
+823811.00% |
| 2017-12-31 | AU$100.00 ≈ $70.76 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EZZ Life Science Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1931801600.0% over the analyzed period, indicating profitable operations and earnings retention.
EZZ Life Science Holdings Ltd Net Assets Breakdown (December 2024)
EZZ Life Science Holdings Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | AU$19.32 Million | 68.78% |
| Common Stock | AU$8.74 Million | 31.11% |
| Other Comprehensive Income | AU$30.52K | 0.11% |
| Total Equity | AU$28.09 Million | 100.00% |
EZZ Life Science Holdings Ltd Competitors by Market Cap
The table below lists competitors of EZZ Life Science Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Nordic Healthbrands AB (publ)
ST:NNH
|
$10.00 Million |
|
Merchant House International Ltd
AU:MHI
|
$10.00 Million |
|
Alvo Minerals Ltd
AU:ALV
|
$10.01 Million |
|
Zantat Holdings Berhad
KLSE:0301
|
$10.01 Million |
|
Rocket One Inc.
NASDAQ:RKTO
|
$9.98 Million |
|
Moatable Inc
NYSE:MTBLY
|
$9.98 Million |
|
SACCHERIA F.LLI FRANCES.
F:YV1
|
$9.98 Million |
|
Art Nirman Limited
NSE:ARTNIRMAN
|
$9.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EZZ Life Science Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,322,838 to 28,085,315, a change of 6,762,477 (31.7%).
- Net income of 6,730,441 contributed positively to equity growth.
- Dividend payments of 1,817,060 reduced retained earnings.
- Other comprehensive income increased equity by 14,359.
- Other factors increased equity by 1,834,737.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$6.73 Million | +23.96% |
| Dividends Paid | AU$1.82 Million | -6.47% |
| Other Comprehensive Income | AU$14.36K | +0.05% |
| Other Changes | AU$1.83 Million | +6.53% |
| Total Change | AU$- | 31.71% |
Book Value vs Market Value Analysis
This analysis compares EZZ Life Science Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.49x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 126000.00x to 0.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | AU$0.00 | AU$0.30 | x |
| 2018-12-31 | AU$0.02 | AU$0.30 | x |
| 2019-12-31 | AU$0.19 | AU$0.30 | x |
| 2020-12-31 | AU$0.24 | AU$0.30 | x |
| 2021-12-31 | AU$0.27 | AU$0.30 | x |
| 2022-12-31 | AU$0.34 | AU$0.30 | x |
| 2023-12-31 | AU$0.49 | AU$0.30 | x |
| 2024-12-31 | AU$0.61 | AU$0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EZZ Life Science Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.96%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.06%
- • Asset Turnover: 1.97x
- • Equity Multiplier: 1.21x
- Recent ROE (23.96%) is below the historical average (33.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 99.99% | 7.36% | 3.84x | 3.54x | AU$741.42K |
| 2019 | 20.20% | 9.16% | 1.49x | 1.48x | AU$800.83K |
| 2020 | 20.09% | 9.11% | 1.85x | 1.19x | AU$1.02 Million |
| 2021 | 11.53% | 8.74% | 1.05x | 1.25x | AU$173.67K |
| 2022 | 24.89% | 9.77% | 2.11x | 1.21x | AU$2.17 Million |
| 2023 | 32.66% | 10.48% | 2.60x | 1.20x | AU$4.83 Million |
| 2024 | 23.96% | 10.06% | 1.97x | 1.21x | AU$3.92 Million |
Industry Comparison
This section compares EZZ Life Science Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,206,087
- Average return on equity (ROE) among peers: -128.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EZZ Life Science Holdings Ltd (EZZ) | AU$27.81 Million | 99.99% | 0.17x | $9.99 Million |
| Adalta Ltd (1AD) | $7.49 Million | -79.00% | 0.24x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $4.14 Million | -76.87% | 0.39x | $12.88 Million |
| ACRUX Ltd (ACR) | $11.28 Million | 0.00% | 0.07x | $2.61 Million |
| Actinogen Medical Ltd (ACW) | $346.99K | -440.69% | 0.34x | $92.21 Million |
| Argenica Therapeutics Ltd (AGN) | $7.67 Million | -62.81% | 0.24x | $8.63 Million |
| Arovella Therapeutics Ltd (ALA) | $3.77 Million | -28.27% | 0.24x | $42.76 Million |
| Anatara Lifesciences Ltd (ANR) | $535.97K | -364.70% | 1.14x | $1.40 Million |
| Alterity Therapeutics Ltd (ATH) | $16.68 Million | -32.69% | 0.05x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $8.61 Million | -25.79% | 0.06x | $32.32 Million |
| Avecho Biotechnology Ltd (AVE) | $51.55 Million | -176.92% | 0.34x | $32.81 Million |
About EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consum… Read more